Research programme: histamine H3 antagonists - Johnson and Johnson
Alternative Names: 13g; JNJ 10181457; JNJ-28583867; JNJ-7737782; RWJ 662733Latest Information Update: 14 Jan 2022
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Isoquinolines; Morpholines; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists; Serotonin plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders; Major depressive disorder; Sleep disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sleep-disorders in USA (PO)